RCI001 Eye Drops 0.25% in Healthy Adult Male Participants
5 июня 2026 г. обновлено: Rudacure
A Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Administration Phase 1 Clinical Trial to Investigate the Pharmacokinetics, Safety, and Tolerability of RCI001 Eye Drops 0.25% in Healthy Male Subjects
This study is being conducted to evaluate the safety, tolerability, and pharmacokinetics of RCI001 eye drops 0.25% in healthy adult male participants. Pharmacokinetics means how the study drug is absorbed, distributed, and eliminated from the body over time.
Participants who meet the study requirements will be randomly assigned to receive either RCI001 eye drops 0.25% or placebo eye drops. The study treatment will be administered to the left eye according to the assigned dosing schedule. The study includes single-dose administration schedules and multiple-dose administration schedules for up to 15 days.
The study will monitor safety and tolerability through adverse event assessments, vital signs, physical examinations, electrocardiograms, laboratory tests, eye symptom assessments, and ophthalmic examinations. Blood samples will be collected at scheduled time points to measure the concentration of RCI001 in the blood.
Approximately 40 healthy adult male participants are planned to take part in this study.
Обзор исследования
Статус
Завершенный
Условия
Вмешательство/лечение
Тип исследования
Интервенционный
Регистрация (Действительный)
40
Фаза
- Фаза 1
Контакты и местонахождение
В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.
Места учебы
-
-
-
Seoul, Южная Корея
- Seoul national unversity hospital
-
-
Критерии участия
Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.
Критерии приемлемости
Возраст, подходящий для обучения
- Взрослый
Принимает здоровых добровольцев
Да
Описание
Inclusion Criteria:
- Healthy adult male volunteers aged 19 to 50 years at screening.
- Body weight of 50.0 kg to 90.0 kg and body mass index (BMI) of 18.5 kg/m2 to 29.9 kg/m2 at screening.
- Participants who have received sufficient explanation about the study, fully understand the study, voluntarily decide to participate, and provide written informed consent to comply with study requirements.
- Participants who are considered eligible for this study by the investigator based on physical examination, clinical laboratory tests, medical interview, and other screening assessments.
Exclusion Criteria:
- Participants with a current or past history of clinically significant disease in the hepatobiliary system, kidney, nervous system, immune system, respiratory system, gastrointestinal system, endocrine system, hematologic or oncologic system, cardiovascular system, urinary system, or psychiatric system, including but not limited to severe hepatic impairment, viral hepatitis, severe renal impairment, heart failure, Torsade de pointes, mood disorder, or obsessive-compulsive disorder.
- Participation in another clinical trial, including a bioequivalence study, and administration of an investigational product within 6 months before the first planned administration of the investigational product.
- Current smoker who cannot stop smoking during the study period. Participants who stopped smoking at least 3 months before the first planned administration of the investigational product may be eligible.
- Consumption of grapefruit, grapefruit juice, or grapefruit-containing foods from 3 days before the first planned administration of the investigational product until the end of the study, or inability to abstain from grapefruit-containing foods and beverages during this period.
- Participants who are considered unsuitable for participation in the study by the investigator for any other reason.
Учебный план
В этом разделе представлена подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Последовательное назначение
- Маскировка: Четырехместный
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: RCI001 Eye Drops 0.25%, Single-Day Administration, Once Daily
|
RCI001 eye drops 0.25% administered to the left eye according to the assigned dosing schedule.
Другие имена:
|
|
Плацебо Компаратор: Placebo Eye Drops, Single-Day Administration, Once Daily
|
Matching placebo eye drops administered to the left eye according to the assigned dosing schedule.
Другие имена:
|
|
Экспериментальный: RCI001 Eye Drops 0.25%, Single-Day Administration, Twice Daily
|
RCI001 eye drops 0.25% administered to the left eye according to the assigned dosing schedule.
Другие имена:
|
|
Плацебо Компаратор: Placebo Eye Drops, Single-Day Administration, Twice Daily
|
Matching placebo eye drops administered to the left eye according to the assigned dosing schedule.
Другие имена:
|
|
Экспериментальный: RCI001 Eye Drops 0.25%, Single-Day Administration, Four Times Daily
|
RCI001 eye drops 0.25% administered to the left eye according to the assigned dosing schedule.
Другие имена:
|
|
Плацебо Компаратор: Placebo Eye Drops, Single-Day Administration, Four Times Daily
|
Matching placebo eye drops administered to the left eye according to the assigned dosing schedule.
Другие имена:
|
|
Экспериментальный: RCI001 Eye Drops 0.25%, Multiple-Day Administration, Twice Daily
|
RCI001 eye drops 0.25% administered to the left eye according to the assigned dosing schedule.
Другие имена:
|
|
Плацебо Компаратор: Placebo Eye Drops, Multiple-Day Administration, Twice Daily
|
Matching placebo eye drops administered to the left eye according to the assigned dosing schedule.
Другие имена:
|
|
Экспериментальный: RCI001 Eye Drops 0.25%, Multiple-Day Administration, Four Times Daily
|
RCI001 eye drops 0.25% administered to the left eye according to the assigned dosing schedule.
Другие имена:
|
|
Плацебо Компаратор: Placebo Eye Drops, Multiple-Day Administration, Four Times Daily
|
Matching placebo eye drops administered to the left eye according to the assigned dosing schedule.
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Number of Participants With Adverse Events
Временное ограничение: From informed consent through the post-study visit, up to Day 18 for single-administration cohorts and up to Day 32 for multiple-administration cohorts
|
The number and percentage of participants with adverse events will be summarized by treatment group.
Adverse events will be assessed for seriousness, severity, relationship to the study drug, action taken, outcome, and whether they are treatment-emergent adverse events.
|
From informed consent through the post-study visit, up to Day 18 for single-administration cohorts and up to Day 32 for multiple-administration cohorts
|
|
Number of Participants With Clinically Significant Abnormalities in Safety Assessments
Временное ограничение: From baseline through the post-study visit, up to Day 18 for single-administration cohorts and up to Day 32 for multiple-administration cohorts
|
Safety assessments will include vital signs, physical examinations, 12-lead electrocardiograms, clinical laboratory tests, ocular symptom assessments, and ophthalmic examinations.
Clinically significant abnormalities will be summarized by treatment group.
|
From baseline through the post-study visit, up to Day 18 for single-administration cohorts and up to Day 32 for multiple-administration cohorts
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Time to Maximum Plasma Concentration (Tmax) of RCI001 After Single Administration
Временное ограничение: Predose on Day -1 through Day 11
|
Tmax will be calculated from plasma RCI001 concentration-time data after single administration.
|
Predose on Day -1 through Day 11
|
|
Maximum Observed Plasma Concentration (Cmax) of RCI001 After Single Administration
Временное ограничение: Predose on Day -1 through Day 25
|
Cmax will be calculated from plasma RCI001 concentration-time data after single administration.
|
Predose on Day -1 through Day 25
|
|
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of RCI001 After Single Administration
Временное ограничение: Predose on Day -1 through Day 11.
|
AUClast will be calculated from plasma RCI001 concentration-time data after single administration.
|
Predose on Day -1 through Day 11.
|
|
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf) of RCI001 After Single Administration
Временное ограничение: Predose on Day -1 through Day 11.
|
AUCinf will be calculated from plasma RCI001 concentration-time data after single administration.
|
Predose on Day -1 through Day 11.
|
|
Terminal Elimination Half-Life (t1/2) of RCI001 After Single Administration
Временное ограничение: Predose on Day -1 through Day 11.
|
Terminal elimination half-life will be calculated from plasma RCI001 concentration-time data after single administration.
|
Predose on Day -1 through Day 11.
|
|
Apparent Clearance (CL/F) of RCI001 After Single Administration
Временное ограничение: Predose on Day -1 through Day 11.
|
CL/F will be calculated from plasma RCI001 concentration-time data after single administration.
|
Predose on Day -1 through Day 11.
|
|
Apparent Volume of Distribution (Vz/F) of RCI001 After Single Administration
Временное ограничение: Predose on Day -1 through Day 11.
|
Vz/F will be calculated from plasma RCI001 concentration-time data after single administration.
|
Predose on Day -1 through Day 11.
|
|
Time to Maximum Plasma Concentration at Steady State (Tmax,ss) of RCI001 After Multiple Administration
Временное ограничение: Predose on Day -1 through Day 25.
|
Tmax,ss will be calculated from plasma RCI001 concentration-time data after multiple administration.
|
Predose on Day -1 through Day 25.
|
|
Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of RCI001 After Multiple Administration
Временное ограничение: Predose on Day -1 through Day 25.
|
Cmax,ss will be calculated from plasma RCI001 concentration-time data after multiple administration.
|
Predose on Day -1 through Day 25.
|
|
Minimum Observed Plasma Concentration at Steady State (Cmin,ss) of RCI001 After Multiple Administration
Временное ограничение: Predose on Day -1 through Day 25.
|
Cmin,ss will be calculated from plasma RCI001 concentration-time data after multiple administration.
|
Predose on Day -1 through Day 25.
|
|
Average Plasma Concentration at Steady State (Cavg,ss) of RCI001 After Multiple Administration
Временное ограничение: Predose on Day -1 through Day 25.
|
Cavg,ss will be calculated from plasma RCI001 concentration-time data after multiple administration.
|
Predose on Day -1 through Day 25.
|
|
Trough Plasma Concentration (Ctrough) of RCI001 After Multiple Administration
Временное ограничение: Predose on Day -1 through Day 25.
|
Ctrough will be calculated from plasma RCI001 concentration-time data after multiple administration.
|
Predose on Day -1 through Day 25.
|
|
Area Under the Plasma Concentration-Time Curve Over the Dosing Interval at Steady State (AUCtau,ss) of RCI001 After Multiple Administration
Временное ограничение: Predose on Day -1 through Day 25.
|
AUCtau,ss will be calculated from plasma RCI001 concentration-time data after multiple administration.
|
Predose on Day -1 through Day 25.
|
|
Terminal Elimination Half-Life at Steady State (t1/2,ss) of RCI001 After Multiple Administration
Временное ограничение: Predose on Day -1 through Day 25.
|
Terminal elimination half-life at steady state will be calculated from plasma RCI001 concentration-time data after multiple administration.
|
Predose on Day -1 through Day 25.
|
|
Apparent Clearance at Steady State (CLss/F) of RCI001 After Multiple Administration
Временное ограничение: Predose on Day -1 through Day 25.
|
CLss/F will be calculated from plasma RCI001 concentration-time data after multiple administration.
|
Predose on Day -1 through Day 25.
|
|
Apparent Volume of Distribution at Steady State (Vz,ss/F) of RCI001 After Multiple Administration
Временное ограничение: Predose on Day -1 through Day 25.
|
Vz,ss/F will be calculated from plasma RCI001 concentration-time data after multiple administration.
|
Predose on Day -1 through Day 25.
|
|
Peak-to-Trough Fluctuation (PTF) of RCI001 After Multiple Administration
Временное ограничение: Predose on Day -1 through Day 25.
|
PTF will be calculated from plasma RCI001 concentration-time data after multiple administration.
|
Predose on Day -1 through Day 25.
|
Соавторы и исследователи
Здесь вы найдете людей и организации, участвующие в этом исследовании.
Спонсор
Следователи
- Главный следователь: SeungHwan Lee, M.D., Ph.D., Seoul National University Hospital
Публикации и полезные ссылки
Лицо, ответственное за внесение сведений об исследовании, добровольно предоставляет эти публикации. Это может быть что угодно, связанное с исследованием.
Общие публикации
- Im ST, Kim HY, Yoon JY, Oh JY, Kim MK, Chung MH, Paik HJ, Kim DH. Therapeutic Effects of Topical 8-Oxo-2'-deoxyguanosine on Ethanol-Induced Ocular Chemical Injury Models. Cornea. 2018 Oct;37(10):1311-1317. doi: 10.1097/ICO.0000000000001671.
- Kim DH, Im ST, Yoon JY, Kim S, Kim MK, Chung MH, Park CK. Comparison of therapeutic effects between topical 8-oxo-2'-deoxyguanosine and corticosteroid in ocular alkali burn model. Sci Rep. 2021 Mar 25;11(1):6909. doi: 10.1038/s41598-021-86440-7.
- Kim SH, Ku YA, Yoo C, Kim YH, Kim DH. Comparison of RCI001 and corticosteroid on the effects on intraocular pressure in mice. Front Med (Lausanne). 2023 Oct 9;10:1256569. doi: 10.3389/fmed.2023.1256569. eCollection 2023.
- Jung YH, Ku YA, Moon J, Kim S, Ryu JS, Yoon CH, Chung MH, Kim YH, Kim MK, Kim DH. Efficacy of RCI001 as a therapeutic candidate of dry eye disease in a modified mixed dry eye model. Eye Vis (Lond). 2024 Jun 1;11(1):19. doi: 10.1186/s40662-024-00388-z.
- Kim S, Jang YW, Ku YA, Shin Y, Rahman MM, Chung MH, Kim YH, Kim DH. Investigating the Anti-Inflammatory Effects of RCI001 for Treating Ocular Surface Diseases: Insight Into the Mechanism of Action. Front Immunol. 2022 Mar 24;13:850287. doi: 10.3389/fimmu.2022.850287. eCollection 2022.
- Chung H, Ha Y, Kim YH, Kim DH, Shin D. Ocular Distribution and Pharmacokinetics of 8-Oxo-2'-Deoxyguanosine: A Novel Therapeutic Candidate of Ocular Surface Diseases. J Ocul Pharmacol Ther. 2022 Oct;38(8):561-566. doi: 10.1089/jop.2022.0054.
Даты записи исследования
Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.
Изучение основных дат
Начало исследования (Действительный)
28 октября 2024 г.
Первичное завершение (Действительный)
29 августа 2025 г.
Завершение исследования (Действительный)
20 сентября 2025 г.
Даты регистрации исследования
Первый отправленный
12 мая 2026 г.
Впервые представлено, что соответствует критериям контроля качества
5 июня 2026 г.
Первый опубликованный (Действительный)
11 июня 2026 г.
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
11 июня 2026 г.
Последнее отправленное обновление, отвечающее критериям контроля качества
5 июня 2026 г.
Последняя проверка
1 июня 2026 г.
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- RDC001_101
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
НЕТ
Описание плана IPD
Individual participant data will not be made available to other researchers.
The study has been completed and the results are planned to be submitted for publication.
De-identified individual participant-level data are not planned for external sharing due to participant confidentiality, informed consent, regulatory, legal, and proprietary considerations related to the investigational drug product.
Aggregate results may be disclosed through ClinicalTrials.gov,
scientific publication, and/or regulatory submissions, as applicable.
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Нет
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Нет
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .